# Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

> **NCT04428203** · PHASE1 · COMPLETED · sponsor: **Zin W Myint** · enrollment: 21 (actual)

## Conditions studied

- Prostate Cancer Recurrent
- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Epidiolex Oral Liquid Product
- **DRUG:** Epidiolex Oral Liquid Product
- **DRUG:** Epidiolex Oral Liquid Product

## Key facts

- **NCT ID:** NCT04428203
- **Lead sponsor:** Zin W Myint
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2021-08-20
- **Final completion:** 2021-08-20
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428203, "Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04428203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*